Clinical Trial Update: GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating GS-5829 in combination with fulvestrant or exemestane in advanced estrogen receptor-positive, HER2-negative breast cancer was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• Fulvestrant (fulvestrant)
• GS-5829 (GS-5829)

Snippet

Sponsor: Gilead Sciences | Conditions: Advanced Estrogen Receptor Positive HER2- Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-08-07